233 related articles for article (PubMed ID: 25329115)
1. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.
Nussbaum LA; Dumitraşcu V; Tudor A; Grădinaru R; Andreescu N; Puiu M
Rom J Morphol Embryol; 2014; 55(3):877-84. PubMed ID: 25329115
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
3. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
4. Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
Grădinaru R; Andreescu N; Nussbaum L; Suciu L; Puiu M
Ir J Med Sci; 2019 Nov; 188(4):1417-1422. PubMed ID: 30771137
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 polymorphisms and atypical antipsychotic weight gain.
Ellingrod VL; Miller D; Schultz SK; Wehring H; Arndt S
Psychiatr Genet; 2002 Mar; 12(1):55-8. PubMed ID: 11901361
[TBL] [Abstract][Full Text] [Related]
6. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
7. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
[TBL] [Abstract][Full Text] [Related]
8. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
9. -759C÷T polymorphism of the HTR2C gene is not correlated with atypical antipsychotics-induced weight gain, among Romanian psychotic patients.
Grădinaru RC; Andreescu NI; Nussbaum LA; Farcaş SS; Dumitraşcu V; Suciu L; Puiu M
Rom J Morphol Embryol; 2016; 57(4):1343-1349. PubMed ID: 28174802
[TBL] [Abstract][Full Text] [Related]
10. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
11. Modern molecular study of weight gain related to antidepressant treatment: clinical implications of the pharmacogenetic testing.
Ageu LŞ; Levai CM; Andreescu NI; Grigoraş ML; Hogea LM; Chiriac DV; Folescu R; Bredicean AC; Nussbaum LM; Enătescu VR; Poroch V; Lupu V; Puiu M; Nussbaum LA
Rom J Morphol Embryol; 2018; 59(1):165-173. PubMed ID: 29940625
[TBL] [Abstract][Full Text] [Related]
12. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
[TBL] [Abstract][Full Text] [Related]
13. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
14. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
Barteček R; Juřica J; Zrůstová J; Kašpárek T; Pindurová E; Žourková A
Neuro Endocrinol Lett; 2012; 33(2):236-44. PubMed ID: 22592207
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
16. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
19. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
20. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
